Product news

Share this article:

Otsuka Pharmaceutical and Bristol-Myers Squibb announced that the FDA approved the supplemental NDA for the atypical antipsychotic Abilify (aripiprazole) for the treatment of schizophrenia in adolescents aged 13-17 years. The FDA first approved Abilify for the treatment of schizophrenia in adults on November 15, 2002.

Allergan said the FDA has approved Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%, an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor, for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters